Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 ...

Secure Energy Services Q4 Earnings Call Highlights

Secure Energy Services (TSE:SES) executives said the company delivered higher fourth-quarter profitability and modest full-year growth in 2025 despite weaker commodity prices and reduced ...

Since 1965, Alberta government treated windfall resource revenue increases as permanent by increasing spending nearly half the time

Over the past 60 years, nearly half—45 per cent—of Alberta's windfall resource revenue periods (when resource revenues ...

Ford government fails to achieve its own fiscal goals

Despite Premier Doug Ford's explicit commitment to fiscal policy reforms in the province, Ontario has failed to constrain the ...